Evidence map›Paper›PMID 27236483›Full record

ArticleJournal of chromatography. A2016

Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry.

Karl B Scheidweiler, Matthew N Newmeyer, Allan J Barnes, Marilyn A Huestis

Registry-linked trialOpen access · greenAbstract readValidation Study
In one paragraph

Article in Journal of chromatography. A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06218056 (Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06218056 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use

TypeinterventionalSponsorUniversity of California, Los AngelesRan2024 to 2026Enrolled120ConditionsTobacco Use Disorder, Tobacco Smoking, Tobacco DependenceArmsCannabidiol (CBD) 800 mg, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2017
    Trial
  3. PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  4. Article
  5. Determination of ΔForensic toxicology · 2024
    Article
  6. Article
  7. Article
  8. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Karl B ScheidweilerChemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA. Electronic address: KScheidweiler@intra.nida.nih.gov.
Matthew N NewmeyerChemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; Program in Toxicology, University of Maryland, Baltimore, MD, USA.
Allan J BarnesChemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
Marilyn A HuestisChemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
National Institutes of Health · USNational Institute on Drug Abuse · US

Funding

Pharmacokinetics And Pharmacodynamics Of Smoked Drugs Of AbuseZIADA000413 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$6.0M
Detection Of Drugs Of Abuse In Alternative Biological Fluids And TissuesZIADA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$3.9M
Pharmacokinetics And Pharmacodynamics Of Drugs Of AbuseZIADA000414 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$2.8M
Intramural NIH HHS ZIA DA000412Intramural NIH HHS ZIA DA000413Intramural NIH HHS ZIA DA000414
6 · The paper itself

Abstract

Identifying recent cannabis intake is confounded by prolonged cannabinoid excretion in chronic frequent cannabis users. We previously observed detection times ≤2.1h for cannabidiol (CBD) and cannabinol (CBN) and Δ(9)-tetrahydrocannabinol (THC)-glucuronide in whole blood after smoking, suggesting their applicability for identifying recent intake. However, whole blood collection may not occur for up to 4h during driving under the influence of drugs investigations, making a recent-use marker with a 6-8h detection window helpful for improving whole blood cannabinoid interpretation. Other minor cannabinoids cannabigerol (CBG), Δ9-tetrahydrocannabivarin (THCV), and its metabolite 11-nor-9-carboxy-THCV (THCVCOOH) might also be useful. We developed and validated a sensitive and specific liquid chromatography-tandem mass spectrometry method for quantification of THC, its phase I and glucuronide phase II metabolites, and 5 five minor cannabinoids. Cannabinoids were extracted from 200μL whole blood via disposable pipette extraction, separated on a C18 column, and detected via electrospray ionization in negative mode with scheduled multiple reaction mass spectrometric monitoring. Linear ranges were 0.5-100μg/L for THC and 11-nor-9-carboxy-THC (THCCOOH); 0.5-50μg/L for 11-hydroxy-THC (11-OH-THC), CBD, CBN, and THC-glucuronide; 1-50μg/L for CBG, THCV, and THCVCOOH; and 5-500μg/L for THCCOOH-glucuronide. Inter-day accuracy and precision at low, mid and high quality control (QC) concentrations were 95.1-113% and 2.4-8.5%, respectively (n=25). Extraction recoveries and matrix effects at low and high QC concentrations were 54.0-84.4% and -25.8-30.6%, respectively. By simultaneously monitoring multiple cannabinoids and metabolites, identification of recent cannabis administration or discrimination between licit medicinal and illicit recreational cannabis use can be improved.

Indexed as

Marijuana SmokingBiomarkersCannabidiolCannabinoidsChromatography, LiquidDronabinolGlucuronidesHumansSubstance Abuse DetectionTandem Mass Spectrometry11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acidBiomarkersCannabidiolcannabigerolCannabinoidsDronabinolGlucuronidestetrahydrocannabivarin 9CannabinoidsDisposable pipette extractionRecent use markersWhole blood

Identifiers

PMID27236483
PMCPMC4955402
OpenAlexW2346912294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.